KROS — Keros Therapeutics Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapSuper Stock

Annual balance sheet for Keros Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	—	—	—	—	—
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash and Equivalents
Cash and Short Term Investments	266	230	279	331	560
Net Total Accounts Receivable
Net Total Receivables	0.216	18.2	0	0.143	2.74
Prepaid Expenses
Total Other Current Assets
Total Current Assets	268	251	286	347	589
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	1.6	2.4	17.6	19.5	23.5
Other Long Term Assets
Total Assets	269	255	307	370	616
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Total Other Current Liabilities
Total Current Liabilities	7.18	11.8	16.5	24.4	27.4
Long Term Debt
Total Long Term Debt
Total Debt
Total Other Liabilities
Total Liabilities	7.72	12.1	29.4	37.8	44.3
Redeemable Preferred Stock
Non Redeemable Preferred Stock
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Total Equity	262	243	277	332	572
Total Liabilities & Shareholders' Equity	269	255	307	370	616
Total Common Shares Outstanding